Suicidal Thoughts and Behavior With Antidepressant Treatment
Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine
by Robert D. Gibbons, PhD; C. Hendricks Brown, PhD; Kwan Hur, PhD; John M. Davis, MD; and J. John Mann, MD
Archives of General Psychiatry. Published online February 6, 2012.
-
the people at the National Bureau of Economic Research [News coverage of FDA warnings on pediatric antidepressant use and suicidality]
-
and now Dr. Gibbons with his ninth article related to the topic [Suicidal Thoughts and Behavior With Antidepressant Treatment].
-
A Fresh Look At Antidepressants Finds Low Risk Of Youth Suicide
NPR Health Blog
by Alix Spiegel
Feb 07,2012 -
Study questions antidepressant link to suicide in kids
Los Angeles Times
By Shari Roan
February 06, 2012 -
No Link Between Antidepressant and Suicide in Kids
Study Calls FDA Black Box Warning Into Question
Medscape
by Fran Lowry
February 21, 2012 -
Antidepressant-suicide link in children questioned
by Sharmila Devi
The Lancet. March 3, 2012 379:791. -
Data Diving
What lies untapped beneath the surface of published clinical trial analyses
could rock the world of independent review
The Scientist
By Kerry Grens
May 1, 2012
Benefits From Antidepressants:
Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine
by Robert D. Gibbons, PhD; Kwan Hur, PhD; C. Hendricks Brown, PhD; John M. Davis, MD; and J. John Mann, MD
Archives of General Psychiatry. Published online March 5, 2012.
I’ve never seen an article [one that was not even yet published in the Journal itself] receive so much immediate publicity and so I called it a campaign. But then yesterday, our attention was drawn by Tom to the Grand Rounds schedule in the Psychiatry Department at the University of Miami, new home of the infamous Dr. Charles Nemeroff – and there was Dr. Robert Gibbons giving a Grand Rounds presentation called Do Antidepressants work and do they cause suicide?. Then I looked at the date – February 20, 2012! So, in this case, he’s presenting the results from both studies before the second one was even available online! I can reach no other conclusion than that this Grand Rounds presentation was also part of the media campaign to debunk the FDA’s Black Box Warning, and that it is being somehow orchestrated by sponsors unknown. It’s not lost on us that this Grand Rounds was at Dr. Nemeroff’s Department, suggesting two things to me – PHARMA, and that Dr. Nemeroff is still in the game. Recall that Dr. Nemeroff was an early nay-sayer about the Black Box Warning [Impact of Publicity Concerning Pediatric Suicidality Data on Physician Practice Patterns in the United States]. Things never change, it seems…
We might surmise that after all these years of conferring with pharma marketing people, research psychiatrists now know how to roll out a new idea and get a lot of coverage for it.
Ever get the feeling you’re Neo after he took the red pill in the movie The Matrix? Those of us that have had family members suffer serious adverse reactions from pharma’s “life-saving” products have been down the rathole for quite some time. Fair warning, the further you go the more you find. The more you speak out, the more you will be attacked. I hope you have a strong stomach.
Pharma’s game plan is simple:
1) Manipulate the corrupt peer-review system to promote studies that overstate the effectiveness of your product. (prime example – ghostwriting)
2) Discredit studies or stories that question product safety. Defame critics of your product. (Your post highlights a perfect coordinated example. Have you been attacked on Scienceblogs as a nutty Scientologist yet? If not, it’s coming.)
3) Through lobbying and outright bribery, pass laws and regulations that require public agencies to purchase and individuals to consume your product. (That is why psychotropics are a targeted market, those with “mental illness” can be easily compelled by the state to take the product. Some people need to be forced to do what is good for them, you see.)
4) Shift product liability from industry to the state. (We are not here yet with psychotropics, but this one is coming.)
Please keep up the good work and continue to dig. What you describe aren’t isolated incidents but a clear pattern that we’ve seen before. If nothing else, pharma is predictable.